What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Lymphoma, Internal medicine, Pathology, Rituximab and Surgery are his primary areas of study.
His Lymphoma research is multidisciplinary, relying on both Cancer and Cancer research.
The Internal medicine study combines topics in areas such as Gastroenterology and Oncology.
He has researched Pathology in several fields, including Chlamydiaceae and Anemia.
His study on Rituximab is covered under Immunology.
His study on Chemotherapy, Regimen and Phases of clinical research is often connected to Standard treatment as part of broader study in Surgery.
His most cited work include:
- Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience (501 citations)
- Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. (436 citations)
- Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas (428 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Lymphoma, Rituximab, Diffuse large B-cell lymphoma and Oncology.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery.
His Lymphoma research is multidisciplinary, incorporating elements of Cancer research and Radiation therapy.
In his research, Prednisone is intimately related to Vincristine, which falls under the overarching field of Rituximab.
His study in Diffuse large B-cell lymphoma is interdisciplinary in nature, drawing from both Germinal center, BCL6, Gene expression profiling, CHOP and Aggressive lymphoma.
His Oncology research integrates issues from Survival rate, ThioTEPA, Lenalidomide and Transplantation.
He most often published in these fields:
- Internal medicine (52.89%)
- Lymphoma (51.24%)
- Rituximab (28.93%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (52.89%)
- Lymphoma (51.24%)
- Oncology (26.72%)
In recent papers he was focusing on the following fields of study:
Andrés J.M. Ferreri focuses on Internal medicine, Lymphoma, Oncology, Diffuse large B-cell lymphoma and Rituximab.
His Internal medicine study frequently links to adjacent areas such as Gastroenterology.
Andrés J.M. Ferreri specializes in Lymphoma, namely Primary mediastinal B-cell lymphoma.
His Oncology research is multidisciplinary, incorporating perspectives in Primary central nervous system lymphoma, Chemotherapy, Immunotherapy, Chemoimmunotherapy and Radiation therapy.
His Diffuse large B-cell lymphoma study is concerned with the larger field of Pathology.
His Rituximab study integrates concerns from other disciplines, such as Regimen, Surgery, Transplantation and Vincristine, Cyclophosphamide.
Between 2016 and 2021, his most popular works were:
- Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial (101 citations)
- Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial (84 citations)
- Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy (63 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Andrés J.M. Ferreri mostly deals with Lymphoma, Internal medicine, Rituximab, Oncology and Diffuse large B-cell lymphoma.
His research integrates issues of Immune checkpoint, Positron emission tomography, Cancer research and Randomized controlled trial in his study of Lymphoma.
His research links Surgery with Internal medicine.
His studies deal with areas such as Gastroenterology, Regimen and Vincristine as well as Rituximab.
His work is dedicated to discovering how Oncology, Chemotherapy are connected with Vascular permeability, Blood–brain barrier and Meta-analysis and other disciplines.
His Diffuse large B-cell lymphoma study improves the overall literature in Pathology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
